Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cary C who wrote (15415)	5/5/1999 8:29:00 PM
From: Sergio H	Respond to of 29382

Cary, for the folio thread....SATH at opening price unless you specify enty point in real time. Thanks. AS

To: Cary C who wrote (15415)	9/26/1999 11:17:00 AM
From: Sergio H	Respond to of 29382

VISION STOCKS Very interesting article from the Dallas Morning News: New option for the nearsighted 09/20/99 By Helen Bond / Special Contributor to The Dallas Morning News Eyeglass and contact lens wearers have a new alternative to improve their vision. The procedure, called Intacs, is expected to appeal to mildly nearsighted Americans who are reluctant to undergo other popular but permanent vision-correction operations. Unlike more invasive procedures, such as Lasik, which involves peeling back a flap of the eye's cornea and reshaping the cornea using a laser, doctors insert tiny ring-shaped and transparent implants into the cornea to correct mild nearsightedness. While the eyesight correction is permanent, the procedure doesn't have to be. "The benefits are that the rings can be removed and the cornea by and large can return to where it was before the surgery, should the patient not like this or decide they want a different surgical procedure," says Dr. James McCulley, chairman of ophthalmology at the University of Texas Southwestern Medical Center at Dallas. He also chairs the Food and Drug Administration's ophthalmic device advisory panel. Nearsightedness occurs when a person's cornea - or the eye's front window - is too steeply curved, which hinders the ability to see nearby things more clearly than distant ones. Intacs, which won FDA approval last April, works by flattening the cornea without cutting tissue. Different thicknesses of Intacs correct varying amounts of corneal curvature. The implants are not risk-free: A small percentage of patients had side effects similar to laser surgery, including glare, halos and night-vision problems. The implants can be inserted in a patient's eye in a 15-minute outpatient procedure using local anesthesia. Patients can usually see 15 minutes after the procedure; total recovery time is typically less than three days, Dr. McCulley says. "The person who conceived this approach to treating nearsightedness had an extremely clever idea that proved to be correct," says Dr. McCulley, who, along with a colleague, was the first doctor in Texas trained to perform the procedure. In the future, Intacs is expected to be available for farsightedness and astigmatism, the distorted vision created by an irregularly shaped cornea. The procedure is another step in the progress of corrective-eye surgery that will one day "allow us to customize treatments for the individual cornea," says Dr. McCulley.